1832 Asset Management L.P. Sells 2,544 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• 1832 Asset Management L.P. reduced its stake in Zimmer Biomet by 14.1%, selling 2,544 shares, and now holds a total of 15,469 shares valued at approximately $1.75 million.
• Institutional investors own 88.89% of Zimmer Biomet, with other major stakeholders increasing their positions significantly in the first quarter of the year.
• Zimmer Biomet's recent quarterly earnings report showed an EPS of $2.07, exceeding expectations, along with a revenue increase of 7.0% year-over-year, leading to an updated FY 2025 guidance at 8.100-8.300 EPS.

1832 Asset Management L.P. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,469 shares of the medical equipment provider's stock after selling 2,544 shares during the quarter. 1832 Asset Management L.P.'s holdings in Zimmer Biomet were worth $1,751,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Ameriprise Financial Inc. boosted its position in Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after acquiring an additional 3,208,596 shares in the last quarter. Norinchukin Bank The boosted its position in Zimmer Biomet by 12.8% during the 1st quarter. Norinchukin Bank The now owns 8,980 shares of the medical equipment provider's stock valued at $1,016,000 after acquiring an additional 1,020 shares in the last quarter. CW Advisors LLC boosted its position in Zimmer Biomet by 8.2% during the 1st quarter. CW Advisors LLC now owns 3,123 shares of the medical equipment provider's stock valued at $353,000 after acquiring an additional 236 shares in the last quarter. Summit Financial LLC boosted its position in Zimmer Biomet by 11.8% during the 1st quarter. Summit Financial LLC now owns 2,151 shares of the medical equipment provider's stock valued at $244,000 after acquiring an additional 227 shares in the last quarter. Finally, Humankind Investments LLC boosted its position in Zimmer Biomet by 7.6% during the 1st quarter. Humankind Investments LLC now owns 7,068 shares of the medical equipment provider's stock valued at $800,000 after acquiring an additional 497 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZBH shares. JMP Securities cut their price objective on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Raymond James Financial boosted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $111.44.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $107.3520 on Tuesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $116.71. The firm has a market cap of $21.27 billion, a P/E ratio of 26.12, a PEG ratio of 2.12 and a beta of 0.68. The company has a 50 day moving average of $95.82 and a 200 day moving average of $99.28. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same period in the previous year, the business earned $2.01 EPS. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's payout ratio is currently 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.